Answers are grounded in this paper and cite their sources.
Expert interview highlights quality performance indicators in non-muscle-invasive bladder cancer, suggesting systematic audit-feedback improves surgical outcomes.
Mariappan is a renowned clinician-researcher in the field of urological cancer, with a keen interest in improving the treatment experience and outcomes in patients receiving bladder cancer surgery.Mariappan sits on the European Association of Urology (EAU) Bladder Cancer Guideline panels, and the Core Committee of the International Bladder Cancer Group (IBCG), and is a medical advisor to the Fight Bladder Cancer charity.In this interview, Mariappan discusses the importance of achieving appropriate benchmarks for the treatment of non-muscle-invasive bladder cancer (NMIBC), and evaluates the impact of transurethral resection of bladder tumour (TURBT) on recurrence and progression.He talks about his extensive research and recent publication findings, which aim to establish national quality performance indicator (QPI) programmes that include quality of detrusor muscle sampling and use of single instillation of chemotherapy (mitomycin C; SI-MMC) after TURBT for the improvement of outcomes in patients with bladder cancer.
No takes yet. Share an insight, caveat, or question.
Paramananthan Mariappan (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: